ArticleBMC infectious diseases2026
Effects of antiphospholipid antibodies in the severity and outcome of COVID-19.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveA high prevalence of antiphospholipid antibodies (aPL) has been reported in patients with coronavirus disease 2019 (COVID-19). Although some studies have demonstrated roles for aPL in thrombotic events in COVID-19, findings on their association with disease development and outcomes remain heterogeneous. Therefore, this study investigated whether aPL may serve as effective markers for determining the development and outcome of COVID-19.
methodsSerum samples were isolated from whole blood of 95 individuals with moderate and severe COVID-19. The prevalence of lupus anticoagulant (LA), IgM/IgG antiphospholipid (aPL), IgM/IgG anti-β2-glycoprotein I (aβ2GPI), and IgM/IgG anticardiolipin (aCL) antibodies was measured by enzyme-linked immunosorbent assay. A mixing test was performed in patients with unexplained prolongation of activated partial thromboplastin time (aPTT) to distinguish coagulation factor deficiencies from factor inhibitors. The percentage of selected immune cells and values of biochemical markers were also assessed.
resultsPatients with severe COVID-19 showed significant increases in IgG aβ2GPI and IgG aPL antibody levels compared with individuals with moderate COVID-19 (P < 0.05). The mixing test showed that LA had an increased prevalence in severe patients with unexplained prolongation of aPTT and prothrombin time (PT) (P < 0.01-0.05). No significant differences were observed in IgM/IgG aCL, IgM aPL, or IgM aβ2GPI antibody levels between severe and moderate cases. Additional findings revealed that severe COVID-19 patients who required intensive care unit (ICU) treatment had significant increases in IgM/IgG aPL, IgM/IgG aCL, and IgM/IgG aβ2GPI antibodies (P < 0.01-0.05). However, there was no significant change in the prevalence of LA or IgM aβ2GPI antibodies between severe patients who required ICU therapy and those who did not. IgM aCL and IgG aPL values were significantly higher in non-survivors compared with survivors (P < 0.001-0.05). A similar trend was observed for IgG aCL and IgM aPL levels in non-survivors, although these increases were not statistically significant.
conclusionChanges in aPL levels may be considered effective markers for clarifying the severity and outcome of COVID-19. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.